Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces its interim results for the six months ended 31 October 2024.
Financial Summary for H1 2025
- Revenue was £3.7m (H1 2024: £7.1m)
- Gross margin improved to 56.9% (H1 2024: 54.2%)
- Adjusted EBITDA loss of £2.3m (H1 2024: £0.1m loss)*
- Loss before tax was £5.7m (H1 2024: £3.5m loss)
- Cash and cash equivalents at 31 October 2024 were £0.6m (30 April 2024: £0.5m)
*A reconciliation of adjusted EBITDA can be found in the Financial Review.
You can view the full interim results here
Back to Latest
